PharmaMar announces abstracts to be presented at ASCO 2023

Madrid, May 26th, 2023. – PharmaMar (MSE:PHM) has announced today that the Company and its partners will present seven new abstracts from several clinical trials with Zepzelca® (lurbinectedin) and Yondelis® (trabectedin) at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.

The studies to be presented at the congress include two oral presentations with two PharmaMar compounds. With the abstract entitled: "Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)", Gregory Cote, MD, PhD, medical oncologist at Massachusetts General Hospital, will present updated efficacy and tolerability data on the combination of lurbinectedin with doxorubicin from the phase 1B soft-tissue sarcoma study leading into a randomized phase II trial in leiomyosarcoma (LMS).

Peter Reichardt, MD, Physician-in-Chief of the Interdisciplinary Oncology Clinic HELIOS Klinikum Berlin-Buch, will present the abstract entitled: "Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)", in which he will present efficacy and safety data of trabectedin plus nivolumab as second-line treatment for patients with metastatic or inoperable soft tissue sarcoma, previously treated with anthracyclines. The study confirms the activity of trabectedin plus nivolumab, particularly in patients with lipo- or leiomyosarcomas, suggesting synergistic activity. In addition, the safety of trabectedin and nivolumab was consistent with the safety profiles of each drug separately, with no new findings relevant to the combination.

All ASCO poster presentations are available on request to registered participants for 180 days from May 26, 2023: https://asco.org/abstracts

Highlighted studies at ASCO 2023
<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>TITLE</th>
<th>LEAD AUTHOR</th>
<th>ABSTRACT</th>
</tr>
</thead>
</table>
| Zepzelca® (lurbinectedin) | *Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)* | Gregory Cote | **ABSTRACT:** 11507  
**SESSION TYPE:** Oral Abstract  
**Session S100a**  
**DATE:** June 5, 2023  
11:30 – 14:30 GMT-5 |
|                          | *Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC*                                                                                                                                 | Sophie Cousin | **ABSTRACT:** 8591  
**SESSION TYPE:** Poster Session  
**POSTER:** 218  
**DATE:** June 4, 2023  
8:00 – 11:00 GMT-5 |
|                          | *A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)* | Benjamin Besse | **ABSTRACT:** TPS8613  
**SESSION TYPE:** Poster Session  
**POSTER:** 233a  
**DATE:** June 4, 2023  
8:00 – 11:00 GMT-5 |
|                          | *IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU)* | Nicolas Girard | **ABSTRACT:** 8584  
**SESSION TYPE:** Poster Session  
**POSTER:** 211  
**DATE:** June 4, 2023  
8:00 – 11:00 GMT-5 |
| Yondelis® (trabectedin)  | *Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)* | Peter Reichardt | **ABSTRACT:** 11500  
**SESSION TYPE:** Oral Abstract  
**Session S100a**  
**DATE:** June 5, 2023  
11:30 – 14:30 GMT-5 |
<table>
<thead>
<tr>
<th>Title</th>
<th>Presenter</th>
<th>ABSTRACT:</th>
<th>SESSION TYPE:</th>
<th>POSTER:</th>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES)</td>
<td>Patrick Grohar</td>
<td>11519</td>
<td>Poster Discussion Session</td>
<td>453</td>
<td>June 3, 2023 16:30 – 18:00 GMT-5</td>
</tr>
<tr>
<td>Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA)</td>
<td>Silvia Stacchiotti</td>
<td>11571</td>
<td>Poster Session</td>
<td>505</td>
<td>June, 2023 13:15 – 16:15 GMT-5</td>
</tr>
</tbody>
</table>

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar
PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zeppelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. It also has a preclinical and clinical program in virology. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Yondelis®
Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.
About Zepzelca®
Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinacidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:
Lara Vadillo – Communication Director lvadillo@pharmamar.com
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com
Phone: +34 918466000

Capital Markets & Investor Relations:
José Luis Moreno – Capital Markets & Investor Relations Director
Natalia Amo – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com